NCT05981846View on ClinicalTrials.gov

A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

October 9, 2023

Study Completion Date

November 6, 2023

Conditions
SARS CoV 2 InfectionInfluenza, Human
Interventions
BIOLOGICAL

BIMERVAX

One dose of booster vaccine

BIOLOGICAL

SIIV

One dose

Trial Locations (8)

15011

Hospital HM Modelo, A Coruña

15706

Hospital Clínico Universitario de Santiago, Santiago de Compostela

17001

Hospital Josep Trueta, Girona

29010

Hospital Regional de Málaga, Málaga

47003

Hospital Clínico de Valladolid, Valladolid

08916

Hospital Germans Trias i Pujol, Badalona

08540

CAP Centelles, Centelles

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Hipra Scientific, S.L.U

INDUSTRY

NCT05981846 - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 | Biotech Hunter | Biotech Hunter